By admin 
Long COVID, officially known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC), represents one of the most pressing global health challenges emerging from the pandemic. Affecting an estimated five per cent of the global population, this translates to tens of millions of individuals grappling with its lingering effects. In Canada alone, approximately two million people are believed to be living with long COVID. The condition is characterized by a broad and often fluctuating spectrum of symptoms that persist for at least three months following the initial COVID-19 infection, often extending much longer. The brain-related manifestations are particularly common and distressing, encompassing severe fatigue, a pervasive "brain fog" that impairs cognitive function, significant memory problems, and a marked low mood or even depression. Despite its widespread prevalence and profoundly disruptive impact on daily life, the medical community currently lacks evidence-based treatments for long COVID. This significant gap in care is largely attributable to an incomplete understanding of the underlying biological mechanisms at play within the brain and body.
The CAMH study’s strength lies in its meticulous investigation of the brain’s dopamine system, a critical neural network implicated in a vast array of functions essential for daily living. Dopamine, a vital neurotransmitter, plays a pivotal role in regulating motivation, reward, pleasure, motor control, and various cognitive functions, including attention and working memory. Dopamine-releasing neurons, concentrated in specific brain regions, are the architects of these processes. Dysfunction in this system can manifest as a wide range of neurological and psychiatric symptoms, as observed in conditions like Parkinson’s disease, depression, and attention-deficit/hyperactivity disorder (ADHD).
To probe the integrity of this crucial system in long COVID patients, researchers employed positron emission tomography (PET), a sophisticated imaging technique that allows for the precise measurement of biological activity inside the living brain. Unlike structural imaging methods like MRI, PET scans can visualize and quantify specific molecular targets, offering an unparalleled window into neurotransmitter systems. In this study, the scientists utilized a well-established radioactive tracer designed to bind to dopamine transporters, which are protein markers indicative of the health, density, and integrity of dopamine nerve terminals—the ends of dopamine neurons where neurotransmitters are released and reabsorbed. By comparing the levels of this marker in individuals diagnosed with long COVID against those in healthy control participants, the research team could infer the status of dopamine neurons.
The findings were stark and compelling: individuals with long COVID exhibited substantially lower levels of this dopamine transporter marker across all major areas of the striatum. The striatum is a deep brain structure, a crucial component of the basal ganglia, which is intricately involved in motor control, reward processing, motivation, and decision-making. The observed reduction in marker levels suggests a decreased density of dopamine nerve terminals, essentially indicating damage or loss of dopamine-producing neurons or their projections within this vital brain region. This reduction implies a compromised capacity for dopamine transmission, directly impacting the very functions the striatum is designed to orchestrate.
Furthermore, the study revealed a remarkable correlation between specific patterns of dopamine marker loss and distinct long COVID symptoms. Lower levels of the dopamine transporter marker in the ventral striatum, a region particularly associated with reward and motivation, were directly linked to a greater reported loss of motivation in patients. This finding offers a biological underpinning for the profound anhedonia and lack of drive often described by long COVID sufferers. Reductions in the dorsal putamen, a part of the striatum predominantly involved in motor control and habit formation, were associated with slower movement, explaining the motor sluggishness and lack of coordination some patients experience. Lastly, lower levels in the caudate putamen, a region critical for goal-directed behavior, learning, and memory, were robustly connected with significant memory difficulties, providing a physiological basis for the debilitating brain fog and cognitive impairment.
"Our findings provide compelling evidence that long COVID involves the loss of dopamine-releasing neurons," stated Dr. Jeffrey Meyer, Senior Scientist at the Brain Health Imaging Centre, Canada Research Chair, and senior author of the study. Dr. Meyer, a world-renowned expert in brain imaging and neurotransmitter systems, emphasized the profound implications of this discovery. "This kind of injury is well known to produce symptoms like lack of motivation and motor slowing, and may contribute to memory difficulties in other neurological conditions. Our results suggest a similar process is occurring in long COVID." This comparison to other neurological conditions, where dopamine dysfunction is a central feature, elevates the significance of the CAMH findings, positioning long COVID within a recognized framework of neurodegenerative or neuroinflammatory disorders.
These new insights are not isolated but rather build upon a foundation of earlier research conducted by the same CAMH team. Previous work had demonstrated that people with long COVID exhibited unusually high levels of inflammation within the brain. Importantly, this neuroinflammation appeared to be particularly pronounced in brain regions known to contain large numbers of dopamine-releasing neurons. This prior discovery provided a crucial hint, suggesting a potential link between inflammation and the subsequent impairment of dopamine pathways.
"We know that inflammation can injure dopamine neurons. While our earlier research showed high levels of inflammation in those regions, this study provides direct evidence that the dopamine neuron marker is reduced in the same regions—and that this loss correlates with patients’ symptoms," Dr. Meyer elaborated. This sequential discovery forms a powerful narrative: the initial observation of brain inflammation, followed by the direct demonstration of dopamine neuron damage in the same areas, strongly suggests a causal or at least a tightly linked relationship. Taken together, these two studies paint a clearer picture of long COVID’s neurological underpinnings, pointing towards a possible connection where persistent brain inflammation directly contributes to or instigates damage involving the delicate and vital dopamine system.
The implications of these results are profound, signaling a potential paradigm shift in how researchers approach the biology and, crucially, the treatment of long COVID. Much of the previous scientific endeavor into long COVID’s mechanisms has understandably centered on systemic inflammation, immune dysregulation, and general neuroinflammation. While these avenues remain critical, the direct evidence of dopamine system damage pivots the focus towards a more specific neurological target. By comparison, very few clinical trials to date have specifically and directly focused on interventions designed to modulate or restore the function of dopamine-releasing neurons.
"These results indicate that long COVID is, at least in part, a disorder of the brain’s dopamine system," Dr. Meyer added, underscoring the transformative nature of this finding. This reclassification, from a nebulous syndrome to one with a defined neurological pathway, opens up immediate and actionable therapeutic strategies. "This suggests that repurposing medications that augment the function of dopamine-releasing neurons, including dopamine precursors and inhibitors of dopamine metabolism, could be a promising approach." Dopamine precursors, such as L-DOPA (levodopa), are compounds that the brain can convert into dopamine, effectively boosting its supply. Inhibitors of dopamine metabolism, such as MAO-B inhibitors or COMT inhibitors, work by preventing the breakdown of dopamine in the brain, thereby prolonging its availability and action. These classes of drugs are already approved and widely used for conditions like Parkinson’s disease, offering a significant advantage for rapid clinical translation due to their known safety profiles and mechanisms of action.
For the millions of people living with long COVID, these findings offer more than just scientific validation; they provide a biological explanation for symptoms that have often been dismissed, misunderstood, or difficult to quantify objectively. The experience of living with an "invisible illness" that lacks clear diagnostic markers or effective treatments can be incredibly isolating and frustrating.
Susan Deuville, a lived experience research advisor to Dr. Meyer, articulated this profound sense of validation: "For five years I have been seeking answers on what happened to me after I contracted COVID in 2021. It was a crushing loss of the life I had and the person I was before. The research of Dr. Meyer brings hope. It also validates what long COVID sufferers have always known—long COVID is real and the effects are devastating." This testimonial underscores the immense psychological and emotional relief that a clear biological explanation can provide, transforming an ambiguous suffering into a recognized medical condition with potential pathways to recovery.
Building directly on these pivotal results, the CAMH researchers are not resting on their laurels. They plan to embark on a crucial next step: a clinical trial targeting dopamine function in people with long COVID, slated to commence in the upcoming couple of months. This trial represents a tangible and immediate translation of their research into potential patient benefit. The primary goal of this intervention study will be to rigorously determine whether modifying dopamine activity, likely through the repurposing of existing dopamine-enhancing medications, can effectively improve the debilitating symptoms of memory impairment, loss of motivation, and profound fatigue that characterize long COVID.
This forthcoming clinical trial will be conducted in collaboration with University Health Network (UHN), a testament to the power of inter-institutional partnership in advancing medical science. This collaboration is part of a broader, strategic alliance between the hospitals, specifically aimed at bridging the historical gap between mental and physical health care. Long COVID, with its intricate blend of physical, neurological, and psychological symptoms, serves as a powerful example of why such integrated approaches are not just beneficial, but essential. The study itself received vital support from the Canadian Institutes of Health Research (CIHR), Canada’s federal funding agency for health research, underscoring the national importance and scientific rigor of this work.
The CAMH study marks a significant turning point in the understanding and potential treatment of long COVID. By providing robust evidence of dopamine neuron damage, it offers a concrete biological target for therapeutic intervention and validates the lived experience of millions. As the upcoming clinical trial moves forward, the hope is that this pioneering research will pave the way for the first evidence-based treatments, bringing much-needed relief and restoring quality of life to those whose lives have been irrevocably altered by the long shadow of COVID-19.
